Insider trading

Period: 120 months Stock: VRTX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

738 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

738 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

738 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

738 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
738 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
738 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

738 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
15 Nov 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold on a plan
$7.03K 19 at 369.92
0.1%
Planned (10b5-1)
14 Nov 2023
Bozic Carmen EVP and CMO
Sold on a plan
$2.15M 5,650 at 380.82
16.2%
Planned (10b5-1)
13 Nov 2023
Kewalramani Reshma CEO & President
Sold on a plan
$1.92M 5,097 at 377.00
4.3%
Planned (10b5-1)
6 Nov 2023
SACHS BRUCE I Director
Sold on a plan
$4.33M 11,250 at 385.00
22.0%
Planned (10b5-1)
31 Oct 2023
Bozic Carmen EVP and CMO
Sold on a plan
$2.01M 5,651 at 355.92
13.9%
Planned (10b5-1)
17 Oct 2023
Bozic Carmen EVP and CMO
Sold on a plan
$2.11M 5,651 at 373.25
12.2%
Planned (10b5-1)
17 Oct 2023
Sold on a plan
$91.13K 243 at 375.00
5.9%
Planned (10b5-1)
16 Oct 2023
LEIDEN JEFFREY M Executive Chairman
Sold on a plan
$4.85M 12,962 at 374.00
36.6%
Planned (10b5-1)
6 Oct 2023
Sold on a plan
$87.12K 242 at 360.00
5.5%
Planned (10b5-1)
3 Oct 2023
Bozic Carmen EVP and CMO
Sold on a plan
$1.95M 5,651 at 345.28
10.9%
Planned (10b5-1)
2 Oct 2023
Biller Jonathan EVP and Chief Legal Officer
Sold on a plan
$211.52K 610 at 346.76
5.5%
Planned (10b5-1)
19 Sep 2023
Bozic Carmen EVP and CMO
Sold on a plan
$1.98M 5,651 at 351.00
9.8%
Planned (10b5-1)
5 Sep 2023
Bozic Carmen EVP and CMO
Sold on a plan
$1.99M 5,651 at 352.66
8.9%
Planned (10b5-1)
23 Aug 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold on a plan
$887.50K 2,500 at 355.00
4.9%
Planned (10b5-1)
10 Aug 2023
Sachdev Amit EVP, Chief Patient Officer
Sold on a plan
$3.51M 10,031 at 350.00
14.6%
Planned (10b5-1)
10 Aug 2023
Sold on a plan
$3.50M 10,000 at 350.00
60.5%
Sold half or more
10 Aug 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold on a plan
$1.99M 5,750 at 345.79
10.1%
Planned (10b5-1)
9 Aug 2023
Sold on a plan
$83.61K 242 at 345.51
5.2%
Planned (10b5-1)
9 Aug 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold on a plan
$21.77K 63 at 345.51
0.2%
Planned (10b5-1)
17 Jul 2023
SACHS BRUCE I Director
Sold on a plan 3×
$4.01M 11,250 at 356.75
22.0%
Planned (10b5-1)
17 Jul 2023
Kewalramani Reshma CEO & President
Sold on a plan
$2.78M 7,828 at 355.00
6.2%
Planned (10b5-1)
15 Jun 2023
Sold on a plan
$3.00M 8,603 at 349.00
13.2%
Planned (10b5-1)
30 May 2023
Ambrose Kristen SVP & Chief Accounting Officer
Sold on a plan
$95.32K 289 at 329.82
4.1%
Planned (10b5-1)
30 May 2023
Sold on a plan
$27.05K 82 at 329.82
0.1%
Planned (10b5-1)
8 May 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan
$997.50K 2,850 at 350.00
8.2%
Planned (10b5-1)
8 May 2023
LEIDEN JEFFREY M Executive Chairman
Sold on a plan
$392.63K 1,125 at 349.00
3.1%
Planned (10b5-1)
5 May 2023
LEIDEN JEFFREY M Executive Chairman
Sold on a plan 2×
$307.26K 879 at 349.56
2.4%
Planned (10b5-1)
5 May 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan
$147.71K 422 at 350.03
1.2%
Planned (10b5-1)
3 May 2023
LEIDEN JEFFREY M Executive Chairman
Sold on a plan 3×
$1.58M 4,508 at 350.11
10.8%
Planned (10b5-1)
3 May 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan 2×
$975.42K 2,781 at 350.74
7.3%
Planned (10b5-1)
2 May 2023
LEIDEN JEFFREY M Executive Chairman
Sold on a plan 3×
$2.26M 6,450 at 349.89
13.3%
Planned (10b5-1)
2 May 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan 3×
$568.77K 1,622 at 350.66
4.1%
Planned (10b5-1)
2 May 2023
Sold on a plan 5×
$202.00K 580 at 348.28
11.1%
Planned (10b5-1)
27 Apr 2023
Kewalramani Reshma CEO & President
Sold on a plan 3×
$1.12M 3,317 at 339.08
2.6%
Planned (10b5-1)
12 Apr 2023
SACHS BRUCE I Director
Sold on a plan 3×
$6.96M 21,300 at 326.73
34.1%
Planned (10b5-1)
12 Apr 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan 3×
$2.47M 7,567 at 326.70
16.0%
Planned (10b5-1)
4 Apr 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan 5×
$164.85K 522 at 315.81
1.1%
Planned (10b5-1)
24 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold on a plan
$539.91K 1,768 at 305.38
3.4%
Planned (10b5-1)
17 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold on a plan 6×
$592.79K 2,000 at 296.39
3.7%
Planned (10b5-1)
16 Mar 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold on a plan 2×
$825.42K 2,746 at 300.59
5.3%
Planned (10b5-1)
13 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 6×
$783.35K 2,666 at 293.83
4.8%
10 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 8×
$604.71K 2,088 at 289.61
3.6%
27 Feb 2023
Sold, plan not stated 3×
$1.45M 5,034 at 287.47
8.2%
27 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 3×
$1.22M 4,238 at 287.51
11.7%
27 Feb 2023
Ambrose Kristen SVP & Chief Accounting Officer
Sold, plan not stated 3×
$347.07K 1,207 at 287.55
14.2%
27 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 3×
$101.77K 354 at 287.48
0.6%
22 Feb 2023
Sold, plan not stated 5×
$706.68K 2,401 at 294.33
3.5%
21 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$1.18M 4,002 at 293.77
9.0%
21 Feb 2023
Sold, plan not stated 4×
$705.60K 2,402 at 293.75
3.4%
21 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 4×
$141.00K 480 at 293.75
0.8%
Showing 151–200 of 738. ← Newer Page 4 of 15 Older →